altretamine has been researched along with Cancer of Ovary in 209 studies
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later." | 9.08 | Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997) |
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 9.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "Lithium carbonate ameliorates neutropenia associated with cancer chemotherapy." | 7.67 | The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. ( Herbst, AL; Makii, MM; Richman, CM; Weiser, PA, 1984) |
| "In women with advanced ovarian cancer, initial therapy with a cisplatin-based combination chemotherapy regimen resulted in higher clinical complete response rates and longer time to failure compared with initial therapy with a single, oral alkylating agent; however, the benefits of this approach were confined to women older than 50 years of age at diagnosis, and there was no significant difference in survival." | 6.68 | Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. ( Carbone, P; Vogl, S; Wadler, S; Yeap, B, 1996) |
| "A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later." | 5.08 | Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997) |
| "Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently." | 5.05 | Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF). ( Carmo-Pereira, J; Costa, FO; Henriques, E; Ricardo, JA, 1981) |
| "A prospective randomized study was conducted in women with suboptimal (greater than or equal to 3 cm residual) Stage III, Stage IV, and recurrent ovarian adenocarcinoma to determine if combination chemotherapy is more effective than melphalan alone in achieving remission and improving survival." | 5.05 | A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. ( Blessing, JA; Buchsbaum, HJ; Homesley, HD; Leone, L; Miller, A; Morrow, CP; Omura, GA, 1983) |
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 5.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "Antitumor activity against advanced ovarian cancer was demonstrated in phase I trials and the drug was quickly incorporated into trials which utilized drug combinations." | 3.76 | Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack? ( Clagett-Carr, K; Foster, BJ; Leyland-Jones, B; Marsoni, S; Simon, R, 1986) |
| "Lithium carbonate ameliorates neutropenia associated with cancer chemotherapy." | 3.67 | The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. ( Herbst, AL; Makii, MM; Richman, CM; Weiser, PA, 1984) |
| "Leukopenia was the dose-limiting toxicity." | 2.70 | Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. ( Bertelsen, K; Havsteen, H; Høyer, M; Jakobsen, A; Malmström, H; Sørensen, P, 2001) |
| " No dose-response relationships were evident above paclitaxel/altretamine 175/150 mg/m2." | 2.70 | A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. ( Davy, M; Egorin, M; Ellis, A; Lüftner, D; Olver, I; Park, SH; Webster, L, 2001) |
| "Altretamine was administered at a dose of 260 mg/m2 orally for 14 days in a 28-day course." | 2.69 | Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. ( Ball, H; Blessing, JA; Lentz, SS; Markman, M; Moore, D, 1998) |
| "27 patients with ovarian cancer FIGO stages IIc-IV were treated with carboplatin 7 x (glomerular filtration rate + 25) mg given intravenously on day 1 and hexamethylmelamine (HMM) 150 mg/m2 orally on days 2-15, every 28 days." | 2.68 | A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. ( Baekelandt, M; Kristensen, GB; Tropé, C; Vergote, IB, 1995) |
| "In women with advanced ovarian cancer, initial therapy with a cisplatin-based combination chemotherapy regimen resulted in higher clinical complete response rates and longer time to failure compared with initial therapy with a single, oral alkylating agent; however, the benefits of this approach were confined to women older than 50 years of age at diagnosis, and there was no significant difference in survival." | 2.68 | Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. ( Carbone, P; Vogl, S; Wadler, S; Yeap, B, 1996) |
| " The treatments were identical in dosage and schedule with the exception of the addition of HMM to one regimen." | 2.67 | A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. ( Greco, FA; Hainsworth, JD; Johnson, DH, 1991) |
| "Forty-six patients with recurrent ovarian cancer were reoperated, and cancer samples for the subrenal capsule assay (SRCA) were collected from 23 of them, whereas this test was not done in the remaining 23 control patients." | 2.67 | Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. ( Venesmaa, P; Ylikorkala, O, 1991) |
| " This study demonstrates that the combination of DDP + HMM is an effective regimen for advanced ovarian carcinoma that yields response rates comparable to other more complex regimens, and that there is a dose-response relationship for DDP in ovarian cancer." | 2.67 | Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. ( Cheuvart, B; Comis, RL; Davis, TE; Falkson, G; Fazzini, E; Horton, J; Kaplan, BH; Vogl, SE; Wiernik, PH; Yeap, B, 1992) |
| "Prednimustine can produce durable responses in advanced ovarian cancer using a schedule that results in negligible toxicity." | 2.66 | Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. ( Cornbleet, MA; Fletcher, S; Kerr, GR; Leonard, RC; Livingstone, JR; Smart, GE; Smyth, JF; Webb, JN, 1989) |
| "Clinical investigation of epithelial ovarian cancer must involve the precise definition of the lesion, careful application of new techniques, the objective evaluation of such techniques, the comparison of results in a randomized fashion with prior forms of therapy, careful pathological evaluation of the tumour, and the evaluation of toxicity to the patient." | 2.65 | Mayo Clinic experience with epithelial ovarian cancer. ( Decker, DG, 1983) |
| "The age adjusted death rate for ovarian cancer has remained unchanged for the past 20 years." | 2.64 | Advances in the staging and treatment of ovarian cancer. ( Fisher, RI; Young, RC, 1977) |
| "Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response." | 2.42 | Recurrent ovarian cancer: how important is it to treat to disease progression? ( Herzog, TJ, 2004) |
| "The standard treatment for ovarian cancer is cytoreductive surgery followed by platinum-based combination chemotherapy." | 2.39 | [Chemotherapy for recurrent ovarian cancer]. ( Chang, C; Imamura, K; Nishimura, H, 1996) |
| "Altretamine is a National Cancer Institute-designated group C antineoplastic agent used in the treatment of advanced ovarian cancer." | 2.38 | Altretamine. ( Hansen, LA; Hughes, TE, 1991) |
| "Two patients diagnosed with stage IIIC ovarian cancer underwent optimal cytoreductive surgery." | 1.32 | Oral altretamine used as salvage therapy in recurrent ovarian cancer. ( Berman, ML; Chan, JK; Loizzi, V; Manetta, A, 2004) |
| " Relative dose intensity was calculated as a fraction of the dosage of a drug in the standard regimen of cyclophosphamide, altretamine, doxorubicin, and platinum (CHAP)." | 1.29 | Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. ( Hryniuk, W; Levin, L; Simon, R, 1993) |
| "The lack of decisive progress in ovarian cancer chemotherapy in recent years led the ARTAC "Ovary" group to initiate a study based on the hypothesis of collateral sensitivities." | 1.28 | [Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group]. ( Coiffier, B; Facchini, T; Filippi, MH; Goudier, MJ; Goupil, A; Mignot, L; Pinel, MC; Pinon, G; Roullet, B; Tresca, P, 1991) |
| "Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug." | 1.28 | Hexamethylmelamine as a single second-line agent in ovarian cancer. ( Larson, JE; Lyter, JA; MacNeill, C; Manetta, A; Podczaski, ES; Scheffler, B; Schein, P, 1990) |
| " This approach does not assume that the underlying dose-response curve is steep; nor does it assume that maximally dose-intense regimens are clinically appropriate in all situations." | 1.28 | Selecting drug combinations based on total equivalent dose (dose intensity) ( Korn, EL; Simon, R, 1990) |
| " The treatment regimens were identical in dosage and schedule with the exception of the addition of HMM to one regimen." | 1.28 | The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). ( Burnett, LS; Greco, FA; Hainsworth, JD; Johnson, DH; Jones, HW, 1990) |
| "In patients with advanced ovarian cancer, initial treatment with combination chemotherapy, including cyclophosphamide and cis-platinum diamminedichloride (cis-platinum), produces response and progression-free survival results which are superior to those achieved with alkylating single-agent chemotherapy." | 1.27 | Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5. ( Neijt, JP; Pinedo, HM; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Vriesendorp, R, 1984) |
| "Eighteen women with bulky ovarian cancer at the start of chemotherapy were brought to second laparotomy after 6 months of combination chemotherapy in an effort to resect previously unresectable tumor masses." | 1.27 | "Second-effort" surgical resection for bulky ovarian cancer. ( Calanog, A; Camacho, F; Greenwald, E; Kaplan, BH; Moukhtar, M; Seltzer, V; Vogl, SE, 1984) |
| "Of 89 samples of cancer cells from ovarian cancer patients primary cultures representative of the cancer cell population could be established in 17." | 1.27 | Clinical correlates of in vitro drug sensitivities of ovarian cancer cells. ( Erba, E; Garattini, S; Ghelardoni, C; Landoni, F; Mangioni, C; Morasca, L; Sessa, C; Vaghi, M, 1983) |
| "Thirty-eight women with advanced ovarian cancer were given monthly cycles of intravenous cyclophosphamide, Adriamycin (doxorubicin) and cis-platin, and oral hexamethylmelamine." | 1.27 | Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. ( Arseneau, J; Bennett, B; Greenwald, E; Kaplan, BH; Pagano, M; Vogl, SE, 1983) |
| "With regard to colony formation of ovarian cancer according to the source of the specimen, the colony-forming rate of solid tumor was high (72%) as compared with 63% for ascites and 43% for pleural effusion." | 1.27 | [Chemotherapy testing for human ovarian cancer using in vitro colony assay]. ( Inoue, K, 1985) |
| " Further phase I studies, with different PMM dosage schedules, are necessary before phase II studies can be recommended." | 1.27 | Hexamethylmelamine and pentamethylmelamine: an update. ( Hahn, DA, 1983) |
| "A series of eight human ovarian cancer lines grown in nude mice were used to compare the activity of hexamethylmelamine (HMM) and N2,N4,N6-trihydroxy methyl-N2,N4,N6-trimethylmelamine (trimelamol)." | 1.27 | Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. ( Boven, E; Erkelens, CA; Nauta, MM; Pinedo, HM; Schlüper, HM, 1986) |
| "For 129 ovarian cancer patients failing prior chemotherapy, overall clinical response rates were: 21% with cisplatin, 36% with cisplatin plus doxorubicin, 52% with cyclophosphamide added to the two drugs, and 44% with hexamethylmelamine added to the three drugs." | 1.27 | Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy. ( Bruckner, HW; Cohen, CJ; Feuer, E; Holland, JF; Kabakow, B; Wallach, RC, 1987) |
| "Fifty-five ovarian cancer patients receiving platinum drug-based chemotherapy have been studied prospectively to determine the extent of formation of the bidentate intrastrand adducts of diammineplatinum covalently attached to the N7 positions of adenosine and/or guanosine in leukocyte DNA." | 1.27 | Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. ( Ozols, RF; Poirier, MC; Reed, E; Tarone, R; Yuspa, SH, 1987) |
| "Phenytoin levels were reduced to 37% of the original values, although the drug was given intravenously." | 1.27 | An interaction between cytostatic and anticonvulsant drugs. ( de Voogd-van der Straaten, I; Neef, C, 1988) |
| "Eleven women with advanced ovarian cancer treated postoperatively with combination chemotherapy (cytoxan, hexamethylmelamine, Adriamycin, and cis-platinum) had disease-free intervals of 5 to 46 months (mean: 22 months) and subsequently developed recurrent carcinoma." | 1.27 | Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. ( Kaplan, B; Seltzer, V; Vogl, S, 1985) |
| "Treatment of patients with advanced ovarian cancer who have failure of first-line chemotherapy is rarely effective." | 1.27 | Intraperitoneal chemotherapy for advanced ovarian cancer. ( Howell, SB; Lucas, WE; Markman, M, 1985) |
| "HMM concentrations in metastases appeared to be higher than in the primary tumor, and in metastases with a diameter less than 3 mm, drug levels were two to ten times those in larger ones." | 1.26 | Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers. ( D'Incalci, M; Farina, P; Garattini, S; Mangioni, C; Sessa, C, 1982) |
| "Twenty-one patients with advanced ovarian cancer proven resistant to standard alkylating chemotherapy were evaluated in a prospective study of Hexamethylmelamine." | 1.26 | Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. ( Bender, RA; Chabner, BA; DeVita, VT; Fisher, RI; Johnson, BL; Young, RC, 1978) |
| "Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV)." | 1.26 | Epithelial carcinoma of the ovary: current strategies. ( Kapp, DS; Katz, ME; Luikart, S; Schwartz, PE, 1981) |
| "Thirteen cases of acute nonlymphocytic leukemia occurred among 5455 patients, as compared to 0." | 1.26 | Acute leukemia after alkylating-agent therapy of ovarian cancer. ( Fraumeni, JF; Hoover, R; Reimer, RR; Young, RC, 1977) |
| "Its activity is most marked in ovarian cancer, lymphomas, and carcinoma of the cervix; the drug is also active in bronchogenic carcinoma and carcinoma of the breast." | 1.26 | Hexamethylmelamine. An evaluation of its role in the therapy of cancer. ( Carter, SK; Legha, SS; Slavik, M, 1976) |
| "Thirty-eight women with advanced ovarian cancer resistant to alkylating-agent chemotherapy were treated with a combination of hexamethylmelamine and cisplatin." | 1.26 | Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. ( Arseneau, JC; Davis, TE; Einhorn, N; Kaplan, BH; Pagano, M; Tunca, JC; Vogl, SE, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 148 (70.81) | 18.7374 |
| 1990's | 49 (23.44) | 18.2507 |
| 2000's | 12 (5.74) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kwon, YS | 1 |
| Nam, JH | 1 |
| Kim, DY | 1 |
| Suh, DS | 1 |
| Kim, JH | 1 |
| Kim, YM | 1 |
| Kim, YT | 1 |
| Keldsen, N | 1 |
| Havsteen, H | 2 |
| Vergote, I | 2 |
| Bertelsen, K | 2 |
| Jakobsen, A | 2 |
| Wang, C | 1 |
| Gu, M | 1 |
| Wang, S | 1 |
| Ma, D | 1 |
| Chan, JK | 1 |
| Loizzi, V | 1 |
| Manetta, A | 3 |
| Berman, ML | 1 |
| Herzog, TJ | 1 |
| Markman, M | 3 |
| Liu, PY | 2 |
| Rothenberg, ML | 2 |
| Monk, BJ | 1 |
| Brady, M | 1 |
| Alberts, DS | 5 |
| Neijt, JP | 11 |
| ten Bokkel Huinink, WW | 11 |
| van der Burg, ME | 10 |
| van Oosterom, AT | 10 |
| Vriesendorp, R | 2 |
| Kooyman, CD | 2 |
| van Lindert, AC | 4 |
| Hamerlynck, JV | 2 |
| van Lent, M | 3 |
| van Houwelingen, JC | 2 |
| Surwit, EA | 1 |
| Crisp, W | 1 |
| Jackson, RA | 1 |
| Grozea, PN | 1 |
| Leigh, S | 1 |
| Carmo-Pereira, J | 2 |
| Costa, FO | 2 |
| Henriques, E | 2 |
| Ricardo, JA | 1 |
| Vogl, SE | 7 |
| Pagano, M | 3 |
| Davis, TE | 3 |
| Einhorn, N | 2 |
| Tunca, JC | 1 |
| Kaplan, BH | 7 |
| Arseneau, JC | 1 |
| Honetz, N | 1 |
| Pino y Torres, JL | 1 |
| Bross, DS | 1 |
| Hernandez, E | 2 |
| Rosenshein, N | 1 |
| Klein, JL | 1 |
| Ettinger, DS | 2 |
| Leichner, PK | 1 |
| Order, SE | 2 |
| Rosenshein, NB | 1 |
| Villar, J | 1 |
| Dillon, MB | 1 |
| Brower, MS | 1 |
| Coleman, M | 3 |
| Pasmantier, MW | 3 |
| Silver, RT | 3 |
| Mamaril, AP | 1 |
| Quiguyan, CC | 1 |
| Davis, BW | 2 |
| Goldhirsch, A | 4 |
| Locher, GW | 1 |
| Dreher, E | 4 |
| Greiner, R | 4 |
| Burki, K | 1 |
| Brunner, KW | 3 |
| de Gramont, A | 2 |
| Krulik, M | 2 |
| Pigne, A | 2 |
| Brissaud, P | 1 |
| Sirinelli, A | 1 |
| Hubert, D | 1 |
| Zylberait, D | 1 |
| Debray, J | 1 |
| Omura, GA | 2 |
| Morrow, CP | 1 |
| Blessing, JA | 2 |
| Miller, A | 1 |
| Buchsbaum, HJ | 2 |
| Homesley, HD | 3 |
| Leone, L | 1 |
| Bruckner, HW | 8 |
| Cohen, CJ | 6 |
| Goldberg, JD | 2 |
| Kabakow, B | 4 |
| Wallach, RC | 2 |
| Deppe, G | 2 |
| Reisman, AZ | 1 |
| Gusberg, SB | 1 |
| Holland, JF | 6 |
| Edwards, CL | 2 |
| Herson, J | 3 |
| Gershenson, DM | 1 |
| Copeland, LJ | 1 |
| Wharton, JT | 4 |
| Herrmann, U | 1 |
| Locher, G | 2 |
| Hainsworth, JD | 4 |
| Malcolm, A | 1 |
| Johnson, DH | 3 |
| Burnett, LS | 4 |
| Jones, HW | 4 |
| Greco, FA | 6 |
| Greenwald, E | 4 |
| Arseneau, J | 2 |
| Bennett, B | 1 |
| Hahn, DA | 1 |
| Giannattasio, M | 1 |
| Rizzi, R | 1 |
| Coratelli, P | 1 |
| Restaino, A | 1 |
| Selvaggi, L | 1 |
| Ferreri, R | 1 |
| Orlando, E | 1 |
| Ierardi, GM | 1 |
| Granata, A | 1 |
| Bettocchi, S | 1 |
| Morasca, L | 3 |
| Erba, E | 3 |
| Vaghi, M | 1 |
| Ghelardoni, C | 1 |
| Mangioni, C | 9 |
| Sessa, C | 8 |
| Landoni, F | 1 |
| Garattini, S | 4 |
| Garattini, E | 3 |
| Colombo, T | 4 |
| Donelli, MG | 2 |
| Catalani, P | 1 |
| Bianchi, M | 1 |
| D'Incalci, M | 11 |
| Pantarotto, C | 2 |
| Decker, DG | 1 |
| Bruntsch, U | 2 |
| Gallmeier, WM | 2 |
| Piver, MS | 2 |
| Barlow, JJ | 2 |
| Lele, SB | 3 |
| Malfetano, JH | 1 |
| McPhee, ME | 1 |
| ten Berge, RJ | 1 |
| Schellekens, PT | 1 |
| Bruning, PF | 1 |
| Pinedo, HM | 4 |
| Stehman, FB | 1 |
| Ehrlich, CE | 1 |
| Callangan, MF | 1 |
| Onnis, A | 1 |
| Maggino, T | 1 |
| Richman, CM | 2 |
| Makii, MM | 1 |
| Weiser, PA | 2 |
| Herbst, AL | 2 |
| Calciati, A | 1 |
| Clerico, M | 1 |
| Donadio, M | 1 |
| Giaccone, G | 1 |
| Meerpohl, HG | 1 |
| Broggini, M | 2 |
| Coccia, P | 1 |
| Rossi, C | 2 |
| Kohorn, EI | 2 |
| Klein-Angerer, S | 1 |
| Dembo, AJ | 2 |
| Ozols, RF | 9 |
| Young, RC | 13 |
| Thigpen, JT | 2 |
| Vance, RB | 2 |
| Balducci, L | 1 |
| Khansur, T | 2 |
| Seltzer, V | 2 |
| Calanog, A | 1 |
| Moukhtar, M | 4 |
| Camacho, F | 1 |
| Neville, AJ | 1 |
| Gilchrist, KW | 1 |
| Grigorova, TM | 1 |
| Vartanian, LG | 1 |
| Marenich, AF | 2 |
| Balconi, G | 1 |
| Lopez, JA | 1 |
| Krikorian, JG | 1 |
| Dias, SF | 1 |
| Spiers, AS | 1 |
| Finkel, HE | 1 |
| Barnard, DE | 1 |
| Katz, ME | 1 |
| Schwartz, PE | 2 |
| Kapp, DS | 1 |
| Luikart, S | 1 |
| Julian, CG | 1 |
| Richardson, RL | 1 |
| Burnett, L | 1 |
| Hande, KR | 1 |
| Oldham, RK | 1 |
| Paesani, R | 1 |
| De Palo, G | 1 |
| Demicheli, R | 1 |
| Valagussa, P | 1 |
| De Lena, M | 1 |
| Villa, E | 1 |
| Weiss, RB | 1 |
| Wallach, R | 2 |
| Ratner, L | 1 |
| Farina, P | 2 |
| Beggiolin, G | 1 |
| Valente, I | 2 |
| Bolis, G | 6 |
| Colombo, N | 4 |
| Razis, DV | 1 |
| Poulakou, E | 1 |
| Petounis, A | 1 |
| Papadimitriou, G | 1 |
| Kosmides, P | 1 |
| Delides, G | 1 |
| Myers, CE | 2 |
| Hogan, WM | 1 |
| Fuks, Z | 3 |
| Rizel, S | 3 |
| Anteby, SO | 4 |
| Biran, S | 3 |
| Griffith, AB | 1 |
| Tempero, MA | 1 |
| Kessinger, A | 1 |
| Lund, B | 2 |
| Aabo, K | 1 |
| Rørth, M | 1 |
| Hansen, HH | 2 |
| Madonna, R | 1 |
| Lee, CR | 2 |
| Faulds, D | 1 |
| Mäenpää, JU | 1 |
| Heinonen, E | 2 |
| Hinkka, SM | 1 |
| Karnani, P | 1 |
| Klemi, PJ | 1 |
| Korpijaakko, TA | 1 |
| Kuoppala, TA | 1 |
| Laine, AM | 1 |
| Lähde, MA | 1 |
| Nuoranne, EK | 1 |
| Frasci, G | 1 |
| Comella, G | 1 |
| Comella, P | 1 |
| Conforti, S | 1 |
| Mastrantonio, P | 1 |
| Zullo, F | 1 |
| Persico, G | 1 |
| Barker, IK | 1 |
| Crawford, SM | 1 |
| Fell, AF | 1 |
| Moore, DH | 2 |
| Valea, F | 1 |
| Crumpler, LS | 2 |
| Fowler, WC | 2 |
| Levin, L | 2 |
| Simon, R | 3 |
| Hryniuk, W | 2 |
| McGuire, WP | 1 |
| Dorval, T | 1 |
| Beuzeboc, P | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Palangie, T | 1 |
| Pouillart, P | 1 |
| Kristensen, GB | 1 |
| Baekelandt, M | 1 |
| Vergote, IB | 1 |
| Tropé, C | 2 |
| Wadler, S | 1 |
| Yeap, B | 2 |
| Vogl, S | 2 |
| Carbone, P | 1 |
| Nicholson, PW | 1 |
| Ledermann, JA | 1 |
| Rustin, GJ | 2 |
| Nishimura, H | 1 |
| Imamura, K | 1 |
| Chang, C | 1 |
| Edelman, DZ | 1 |
| Peretz, T | 1 |
| Nelstrop, AE | 1 |
| Crawford, M | 1 |
| Ledermann, J | 1 |
| Lambert, HE | 1 |
| Coleman, R | 1 |
| Johnson, J | 1 |
| Evans, H | 1 |
| Brown, S | 1 |
| Oster, W | 1 |
| Moore, D | 1 |
| Ball, H | 1 |
| Lentz, SS | 1 |
| Lotz, JP | 1 |
| Lhommé, C | 1 |
| Pautier, P | 1 |
| Couteau, C | 1 |
| Gligorov, J | 1 |
| Alexandre, J | 1 |
| Selle, F | 1 |
| Izrael, V | 1 |
| Maraninchi, D | 1 |
| Viens, P | 1 |
| Gershanovich, ML | 2 |
| Livshits, ME | 2 |
| Makhnova, EV | 1 |
| Antipenkova, VI | 1 |
| Sørensen, P | 1 |
| Høyer, M | 1 |
| Malmström, H | 1 |
| Wilczynski, S | 1 |
| Hannigan, EV | 1 |
| Weiner, SA | 1 |
| Weiss, GR | 1 |
| Hunter, VJ | 1 |
| Chapman, JA | 1 |
| Tiersten, A | 1 |
| Kohler, PC | 1 |
| Olver, I | 1 |
| Davy, M | 1 |
| Lüftner, D | 1 |
| Park, SH | 1 |
| Egorin, M | 1 |
| Ellis, A | 1 |
| Webster, L | 1 |
| Chabner, BA | 3 |
| Hubbard, SP | 2 |
| Fisher, RI | 4 |
| Bender, RA | 2 |
| Anderson, T | 1 |
| Simon, RM | 2 |
| Canellos, GP | 2 |
| DeVita, VT | 3 |
| Johnson, BL | 1 |
| Bonomi, PD | 1 |
| Mladineo, J | 1 |
| Morrin, B | 1 |
| Wilbanks, G | 1 |
| Slayton, RE | 1 |
| Wollner, D | 1 |
| Vendrik, CP | 1 |
| Roozendaal, KJ | 1 |
| Struyvenberg, A | 1 |
| Garvin, AJ | 1 |
| Costa, J | 1 |
| Hilgers, RD | 2 |
| Moon, TE | 1 |
| Martimbeau, PW | 1 |
| Rivkin, S | 1 |
| Kane, R | 1 |
| Harvey, H | 1 |
| Andrews, T | 1 |
| Bernath, A | 1 |
| Curry, S | 1 |
| Dixon, R | 1 |
| Gottlieb, R | 1 |
| Kukrika, M | 1 |
| Lipton, A | 1 |
| Mortel, R | 1 |
| Ricci, J | 1 |
| White, D | 1 |
| Berenzweig, M | 1 |
| Bulkin, W | 1 |
| Belloni, C | 2 |
| Byrd, R | 1 |
| Malpas, JS | 1 |
| Rutledge, F | 2 |
| Smith, JP | 4 |
| Hodge, MP | 1 |
| Stanhope, CR | 1 |
| Reimer, RR | 1 |
| Hoover, R | 1 |
| Fraumeni, JF | 1 |
| Lewis, GC | 1 |
| Blessing, J | 1 |
| Kardinal, CG | 1 |
| Luce, JK | 1 |
| Barber, HR | 1 |
| Kwon, T | 1 |
| Buterman, I | 1 |
| Kakarla, R | 1 |
| Legha, SS | 1 |
| Slavik, M | 1 |
| Carter, SK | 1 |
| Rutledge, FN | 2 |
| Dalesio, O | 3 |
| Rodenhuis, S | 1 |
| Dubbelman, R | 1 |
| Hilton, A | 1 |
| Franklin, H | 1 |
| Koier, I | 1 |
| van Tinteren, H | 1 |
| Muggia, F | 1 |
| Norris, K | 1 |
| Himmelmann, A | 1 |
| Frankendal, B | 1 |
| Scheistrøen, M | 1 |
| Vlachos, K | 1 |
| Hauge, MD | 1 |
| Long, HJ | 1 |
| Hartmann, LC | 1 |
| Edmonson, JH | 3 |
| Webb, MJ | 1 |
| Su, J | 1 |
| Wiernik, PH | 1 |
| Comis, RL | 1 |
| Falkson, G | 1 |
| Fazzini, E | 1 |
| Cheuvart, B | 1 |
| Horton, J | 1 |
| Pinon, G | 1 |
| Pinel, MC | 1 |
| Goudier, MJ | 1 |
| Coiffier, B | 1 |
| Filippi, MH | 1 |
| Goupil, A | 1 |
| Roullet, B | 1 |
| Facchini, T | 1 |
| Mignot, L | 1 |
| Tresca, P | 1 |
| Willemse, PH | 2 |
| Vermorken, JB | 3 |
| Heintz, AP | 4 |
| Aartsen, E | 1 |
| Venesmaa, P | 1 |
| Ylikorkala, O | 1 |
| MacNeill, C | 2 |
| Lyter, JA | 2 |
| Scheffler, B | 3 |
| Podczaski, ES | 2 |
| Larson, JE | 2 |
| Schein, P | 2 |
| Marsoni, S | 3 |
| Cohen, C | 1 |
| Mandeli, J | 1 |
| Chesser, MR | 2 |
| Holland, J | 1 |
| Schein, PS | 2 |
| McCulloch, W | 1 |
| Brady, MF | 1 |
| Yordan, E | 1 |
| Major, FJ | 1 |
| Park, RC | 1 |
| Hansen, LA | 1 |
| Hughes, TE | 1 |
| Gorbunova, VA | 1 |
| Perevodchikova, NI | 1 |
| Kozachenko, VP | 1 |
| Ryzhakov, VM | 1 |
| Zhordania, KI | 1 |
| Jones, CP | 1 |
| Wils, JA | 1 |
| Cohen, MH | 1 |
| Korn, EL | 1 |
| Torri, V | 1 |
| Valsecchi, MG | 1 |
| Bianchi, U | 1 |
| Bonazzi, C | 1 |
| Epis, A | 1 |
| Favalli, G | 1 |
| van der Hoop, RG | 1 |
| van Houwelingen, C | 1 |
| Hansen, M | 1 |
| Thomsen, HK | 1 |
| Sørensen, BL | 1 |
| Nielsen, NC | 1 |
| Lundvall, F | 1 |
| Boogerd, W | 1 |
| Hoppenbrouwers, WJ | 1 |
| van der Sande, JJ | 1 |
| Inoue, K | 1 |
| Patsner, B | 1 |
| Tsukada, Y | 1 |
| Bielat, K | 1 |
| Castillo, NB | 1 |
| Leonard, RC | 1 |
| Smart, GE | 1 |
| Livingstone, JR | 1 |
| Cornbleet, MA | 1 |
| Kerr, GR | 1 |
| Fletcher, S | 1 |
| Webb, JN | 1 |
| Smyth, JF | 1 |
| Feuer, E | 3 |
| Sipilä, P | 1 |
| Kivinen, S | 1 |
| Gröhn, P | 1 |
| Vesala, J | 1 |
| Scarantino, CW | 1 |
| Muss, HB | 1 |
| Welander, CE | 1 |
| Bhardwaj, S | 1 |
| Ang, PT | 1 |
| Kavanagh, J | 1 |
| Griffin, TW | 1 |
| Hunter, RA | 1 |
| Cederbaum, AI | 1 |
| Tak, WK | 1 |
| Ward, AD | 1 |
| Schwartz, JH | 1 |
| Halpin, TF | 1 |
| Strauss, GM | 1 |
| Meyer, RN | 1 |
| Liepman, MK | 1 |
| Brufman, G | 1 |
| Sulkes, A | 1 |
| Milwidsky, A | 1 |
| Weshler, Z | 1 |
| Grosh, WW | 2 |
| Podczaski, E | 1 |
| Abrams, J | 1 |
| Belinson, JL | 1 |
| Pretorius, RG | 1 |
| McClure, M | 1 |
| Ashikaga, T | 1 |
| Drolet, Y | 1 |
| Louvet, C | 1 |
| Dray, C | 1 |
| Lavoie, A | 1 |
| Painchaud, M | 1 |
| Blouin, R | 1 |
| Tessier, C | 1 |
| Tanke, HJ | 1 |
| van Vianen, PH | 1 |
| Emiliani, FM | 1 |
| Neuteboom, I | 1 |
| de Vogel, N | 1 |
| Tates, AD | 1 |
| de Bruijn, EA | 1 |
| Foster, BJ | 1 |
| Clagett-Carr, K | 1 |
| Leyland-Jones, B | 1 |
| Laufman, LR | 1 |
| Green, JB | 1 |
| O'Toole, R | 1 |
| Young, DC | 1 |
| Lin, F | 1 |
| Rivkin, SE | 1 |
| Louie, KG | 1 |
| Ostchega, Y | 1 |
| Jenkins, J | 1 |
| Howser, D | 1 |
| Keating, G | 1 |
| Chambers, JT | 1 |
| Boven, E | 1 |
| Nauta, MM | 1 |
| Schlüper, HM | 1 |
| Erkelens, CA | 1 |
| Grubb, BP | 1 |
| Thant, M | 1 |
| Simon, A | 1 |
| Fields, S | 1 |
| Schenker, JG | 1 |
| Pater, JL | 1 |
| Carmichael, JA | 2 |
| Krepart, GV | 1 |
| Fraser, RC | 1 |
| Roy, M | 1 |
| Kirk, ME | 1 |
| Levitt, M | 1 |
| Brown, LB | 1 |
| Wilson, KS | 1 |
| Shelley, WE | 2 |
| Rosen, GF | 1 |
| Lurain, JR | 1 |
| Newton, M | 1 |
| Wu, BZ | 1 |
| Reed, E | 1 |
| Tarone, R | 1 |
| Yuspa, SH | 1 |
| Poirier, MC | 1 |
| Lichter, AS | 1 |
| Myers, CC | 1 |
| Ostechega, Y | 1 |
| Trimbos, JB | 3 |
| Bouma, J | 1 |
| Jansen, RL | 1 |
| Verweij, J | 1 |
| Stoter, G | 1 |
| Wolff, SN | 1 |
| Neef, C | 1 |
| de Voogd-van der Straaten, I | 1 |
| Krauer, F | 1 |
| Forni, M | 1 |
| Jungi, FW | 1 |
| Veraguth, P | 1 |
| Engeler, V | 1 |
| Zanaboni, F | 1 |
| Aalders, JG | 1 |
| Ross, WM | 1 |
| Schaberg, A | 1 |
| Van der Velde, EA | 1 |
| Nooy, M | 1 |
| George, M | 1 |
| Guastalla, JP | 1 |
| Veenhof, CH | 1 |
| Rotmensz, N | 1 |
| Wieand, HS | 1 |
| McCormack, GW | 2 |
| Posada, JG | 1 |
| Marantz, AB | 1 |
| Yeung, KY | 1 |
| Smith, FP | 2 |
| Delgado, G | 2 |
| Edwards, BK | 1 |
| Kaplan, B | 1 |
| McLaughlin, EK | 1 |
| Tuholski, N | 1 |
| Mermillod, B | 1 |
| Lucas, WE | 1 |
| Howell, SB | 1 |
| Ballard, WP | 1 |
| Fuller, AF | 1 |
| Krane, IM | 1 |
| Budzik, GP | 1 |
| Donahoe, PK | 1 |
| Carlson, JA | 1 |
| Day, TG | 1 |
| Botts, B | 1 |
| Masterson, BJ | 1 |
| Mäenpää, J | 1 |
| Kangas, L | 1 |
| Grönroos, M | 1 |
| Fleming, TR | 1 |
| Cullinan, SA | 1 |
| Krook, JE | 1 |
| Malkasian, GD | 1 |
| Podratz, KC | 1 |
| Mailliard, JA | 1 |
| Jefferies, JA | 1 |
| Barlow, JF | 1 |
| Reinhard, JP | 1 |
| Joss, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy[NCT00003120] | Phase 3 | 308 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 reviews available for altretamine and Cancer of Ovary
| Article | Year |
|---|---|
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2004 |
[Progress in the chemotherapy of ovarian cancer].
Topics: Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; C | 1982 |
[Chemotherapy of advanced epithelial ovarian carcinoma].
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1984 |
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
Chemotherapy of ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo | 1984 |
New drugs and experimental approaches in ovarian cancer treatment.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Aziridines; Benzoquinones; Busulfan; | 1984 |
The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
Topics: Altretamine; Drug Therapy, Combination; Female; Humans; Nervous System Diseases; Ovarian Neoplasms; | 1981 |
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Topics: Altretamine; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Sa | 1995 |
Advances in the chemotherapy of gynecologic cancer.
Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Endometrial Neoplasms; Etoposide; Fema | 1994 |
Second-line chemotherapy for recurrent carcinoma of the ovary.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Hum | 1993 |
Primary treatment of epithelial ovarian malignancies.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 1993 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Adenocarcinoma, Clear Cell; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 1996 |
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neopla | 1996 |
[High-dose chemotherapy in ovarian adenocarcinoma].
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha | 2000 |
Chemotherapy in the management of ovarian carcinoma: a review.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Therapy, Combina | 1979 |
Chemotherapy of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Fluoroura | 1978 |
Chemotherapy of ovarian cancer: past and present.
Topics: Acrylates; Alkylating Agents; Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Do | 1975 |
Role of chemotherapy in the future treatment of ovarian cancer.
Topics: Alkaloids; Altretamine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Prot | 1992 |
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1991 |
The role of hexamethylmelamine in the management of ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-U | 1991 |
Ovarian cancer: new clinical approaches.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Recu | 1991 |
Altretamine.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1991 |
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ | 1986 |
Current status of chemotherapy for ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1988 |
The sequential multiple modality treatment of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1985 |
67 trials available for altretamine and Cancer of Ovary
| Article | Year |
|---|---|
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Agents, Alkylating; Drug Resistance, Neoplas | 2003 |
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Clinical Trial | 1981 |
Multimodality treatment of patients with advanced ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Altretamine; Antibodies, Neoplasm; Carcinoma; Cisplatin; Clinical Trials a | 1982 |
A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; D | 1983 |
Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo | 1983 |
cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Femal | 1983 |
A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.
Topics: Adult; Altretamine; Anemia; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophospha | 1983 |
Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clini | 1983 |
Mayo Clinic experience with epithelial ovarian cancer.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1983 |
Combination chemotherapy and immune capacity in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1984 |
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Tri | 1984 |
Medical Research Council study on chemotherapy in advanced ovarian cancer. Medical Research Council's Working Party on ovarian cancer.
Topics: Aged; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Methotrexate; Middle | 1981 |
Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.
Topics: Adult; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1982 |
The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
Topics: Aged; Altretamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Carbopl | 1995 |
Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 1995 |
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1993 |
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 1995 |
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car | 1996 |
Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Agents, Alkylating; Female; Humans; Middle A | 1996 |
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating | 1997 |
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Agents, Alkylating; Drug Resistance, | 1998 |
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pr | 2001 |
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating | 2001 |
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Administrati | 1978 |
Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Topics: Alkylating Agents; Altretamine; Clinical Trials as Topic; Drug Evaluation; Drug Resistance; Female; | 1979 |
Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
Topics: Altretamine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1979 |
Histologic grade in advanced ovarian cancer.
Topics: Altretamine; Cell Differentiation; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil | 1979 |
Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
Topics: Adult; Aged; Altretamine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistan | 1979 |
Advances in the staging and treatment of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cyclophos | 1977 |
Second trial drugs in ovarian cancer.
Topics: Altretamine; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Female; Fluorou | 1977 |
Ovarian cancer: use of multiple modality programs involving surgery, radiation therapy and chemotherapy.
Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Dactinomycin; Doxoru | 1977 |
Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Topics: Altretamine; Bone Marrow; Clinical Trials as Topic; Digestive System; Drug Evaluation; Drug Therapy, | 1977 |
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin | 1975 |
Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary.
Topics: Adult; Altretamine; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1975 |
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 1992 |
Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.
Topics: Altretamine; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms | 1992 |
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1992 |
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1991 |
Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer.
Topics: Adult; Aged; Altretamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclop | 1991 |
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1991 |
Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1991 |
A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1991 |
Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dose-Respo | 1991 |
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
Topics: Adult; Aged; Altretamine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carc | 1991 |
Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Altretamine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 1991 |
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1990 |
A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1990 |
Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cisplatin; Clinical Trial | 1989 |
Concurrent chemotherapy and single high-dose plus whole abdominopelvic radiation for persistent ovarian carcinoma.
Topics: Abdomen; Altretamine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans | 1989 |
Complete remission at laparotomy: still a gold standard in ovarian cancer?
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
Present optimal therapy in ovarian cancer.
Topics: Alkylating Agents; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical | 1986 |
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ | 1986 |
Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin | 1986 |
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1986 |
CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin | 1986 |
Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1987 |
"Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
Topics: Altretamine; Clinical Trials as Topic; Female; Humans; Ovarian Neoplasms; Prognosis; Triazines | 1987 |
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma; Cispla | 1987 |
The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1987 |
Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy.
Topics: Abdomen; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinic | 1988 |
Carboplatin in combination therapy for ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cl | 1988 |
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cli | 1985 |
The case for combination chemotherapy in the treatment of advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1985 |
Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1985 |
120 other studies available for altretamine and Cancer of Ovary
| Article | Year |
|---|---|
Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.
Topics: Altretamine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dise | 2009 |
Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2000 |
Oral altretamine used as salvage therapy in recurrent ovarian cancer.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Agents, Alkylating; Female; Humans; Middle A | 2004 |
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progressi | 2006 |
Multiagent chemotherapy in relapsing ovarian cancer.
Topics: Altretamine; Bleomycin; Cisplatin; Clone Cells; Drug Therapy, Combination; Female; Humans; Neoplasm | 1983 |
Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Cisplatin; Cystadenocarcinoma; D | 1982 |
Alternating multiagent chemotherapy for advanced ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Agents; Cisplatin; Cyclophosph | 1983 |
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Combined Chemotherapy Protocol | 1984 |
Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluat | 1984 |
[Treatment of advanced ovarian cancer].
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo | 1984 |
[New therapeutic concept for advanced ovarian cancer (FIGO IIb+c, III, IV)].
Topics: Adult; Aged; Altretamine; Cisplatin; Female; Humans; Melphalan; Middle Aged; Neoplasm Staging; Ovari | 1983 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1983 |
Hexamethylmelamine and pentamethylmelamine: an update.
Topics: Altretamine; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Leukemia; Lung Neopla | 1983 |
Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1983 |
Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Cyclopho | 1983 |
Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.
Topics: Altretamine; Animals; Antineoplastic Agents; Female; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Ti | 1983 |
[Chemotherapy of epithelial ovarian carcinoma].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chlorambucil; Cisplatin; Cyc | 1983 |
Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1983 |
Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; | 1984 |
Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1984 |
Repetitive debulking surgery as adjuvant to chemotherapy in advanced epithelial ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1984 |
The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia.
Topics: Agranulocytosis; Altretamine; Cisplatin; Colony-Stimulating Factors; Cyclophosphamide; Doxorubicin; | 1984 |
[Chemotherapy in advanced forms of carcinoma of the ovary].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1984 |
Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma.
Topics: Altretamine; Animals; Antineoplastic Agents; DNA, Neoplasm; Female; Liver; Lymphoma, Large B-Cell, D | 1984 |
The effect of chemotherapy on lymphocyte subpopulations and cell-mediated cytotoxicity in patients with ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Cytoto | 1984 |
"Second-effort" surgical resection for bulky ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modali | 1984 |
The chemotherapy of granulosa cell tumors of the ovary: experience of the Wisconsin Clinical Cancer Center.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha | 1984 |
Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo | 1984 |
[Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Evaluati | 1980 |
Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
Topics: Altretamine; Cell Line; Cells; Female; Humans; Ovarian Neoplasms; Thymidine; Time Factors; Triazines | 1980 |
Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-Platinum, and doxorubicin after failure of prior therapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Therapy, Combination; | 1980 |
cis-Platinum-hexamethylmelamine therapy of advanced ovarian cancer.
Topics: Adult; Altretamine; Cisplatin; Drug Therapy, Combination; Female; Humans; Middle Aged; Nausea; Ovari | 1981 |
Epithelial carcinoma of the ovary: current strategies.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Doxorubicin; Drug Thera | 1981 |
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin | 1981 |
In vivo and in vitro irreversible binding of hexamethylmelamine to liver and ovarian tumor macromolecules of mice.
Topics: Altretamine; Animals; Female; Kinetics; Mice; Mice, Inbred C57BL; Microsomes; Microsomes, Liver; Neo | 1981 |
Prospective study with HEXA-CAF combination in ovarian carcinoma.
Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouraci | 1981 |
Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug T | 1981 |
Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Topics: Altretamine; Animals; Antineoplastic Agents; Female; Kinetics; Mice; Neoplasms, Experimental; Ovaria | 1982 |
Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers.
Topics: Adipose Tissue; Adult; Aged; Altretamine; Chromatography, Gas; Female; Humans; Kinetics; Middle Aged | 1982 |
Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients.
Topics: Adolescent; Adult; Age Factors; Aged; Altretamine; Ascites; Body Weight; Female; Humans; Kinetics; M | 1981 |
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1982 |
Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Topics: Acute Kidney Injury; Adult; Aged; Altretamine; Anemia; Antineoplastic Agents; Antineoplastic Combine | 1982 |
Current concepts in cancer: ovary--treatment for stages III and IV. Chemotherapy in advanced disease.
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; | 1982 |
Current concepts in cancer: ovary--treatment for stages III and IV. The multimodal approach to the treatment of stage III ovarian carcinoma.
Topics: Altretamine; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Ov | 1982 |
Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma.
Topics: Adenocarcinoma, Papillary; Aged; Altretamine; Drug Therapy, Combination; Female; Humans; Melphalan; | 1982 |
cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
Topics: Adult; Aged; Altretamine; Cisplatin; Cystadenocarcinoma; Drug Evaluation; Drug Therapy, Combination; | 1982 |
Hexamethylmelamine tissue concentrations in pelvic cancer patients.
Topics: Adult; Aged; Altretamine; Female; Humans; Middle Aged; Neoplasms; Ovarian Neoplasms; Triazines | 1980 |
Determination of altretamine in human plasma with high-performance liquid chromatography.
Topics: Altretamine; Chromatography, High Pressure Liquid; Female; Food-Drug Interactions; Humans; Indicator | 1994 |
Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Carcinoma; Female; Humans; Middle Aged; Neoplasm Recurr | 1993 |
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamid | 1993 |
[The use of Hexalen (Altretamin, hexamethyl melamine) in chemotherapy of extensive carcinoma of the ovaries].
Topics: Altretamine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Fema | 2000 |
[Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Topics: Adult; Aged; Altretamine; Antineoplastic Agents, Alkylating; Carcinoma; Chemotherapy, Adjuvant; Drug | 2000 |
Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Altretamine; Bone Marrow; Drug Resistance; Female; H | 1978 |
Ovarian cancer. Effective treatment after alkylating-agent failure.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Cisplatin; Cystadenoma; Doxorubicin; Drug Therapy, Combina | 1979 |
Variable oral absorption of hexamethylmelamine in man.
Topics: Absorption; Administration, Oral; Adult; Aged; Altretamine; Female; Half-Life; Humans; Middle Aged; | 1978 |
Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Doxorubicin; Drug Eva | 1979 |
Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Cyclophosphamide; Dox | 1979 |
The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
Topics: Adult; Aged; Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Cyclopho | 1979 |
Ovarian endometrioid carcinoma in an eleven-year-old child.
Topics: Adenocarcinoma; Altretamine; Child; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1979 |
Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
Topics: Adult; Altretamine; Female; Hematologic Diseases; Humans; Ovarian Neoplasms; Peripheral Nervous Syst | 1979 |
Acute leukemia after alkylating-agent therapy of ovarian cancer.
Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; | 1977 |
[Chemotherapy of the ovarian carcinoma (author's transl)].
Topics: Altretamine; Antineoplastic Agents; Chlorambucil; Cisplatin; Cyclophosphamide; Doxorubicin; Drug The | 1977 |
Current concepts in the management of ovarian cancer.
Topics: Adult; Aged; Altretamine; Castration; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil | 1978 |
Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Topics: Altretamine; Animals; Breast Neoplasms; Carcinoma, Bronchogenic; Chemical Phenomena; Chemistry; Drug | 1976 |
Chemotherapy in advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combi | 1975 |
Hexamethylmelamine in platinum-resistant ovarian cancer: how active?
Topics: Altretamine; Carboplatin; Cisplatin; Drug Resistance; Female; Humans; Ovarian Neoplasms | 1992 |
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Carboplatin; Cisplatin; Drug Resistance; Female; Humans | 1992 |
Hexamethylmelamine (altretamine). A discussion of drug action, pharmacology and clinical activity. Philadelphia, Pennsylvania, November 6, 1989. Proceedings.
Topics: Altretamine; Female; Humans; Ovarian Neoplasms | 1991 |
Altretamine for ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Pall | 1991 |
[Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1991 |
Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer.
Topics: Administration, Oral; Altretamine; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; | 1991 |
Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Topics: Altretamine; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pr | 1991 |
[The potentials of combined chemotherapy in disseminated ovarian cancer].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1991 |
Hexamethylmelamine as a single second-line agent in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local | 1990 |
Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1990 |
Ovarian cancer: what is poor prognosis disease?
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1990 |
Selecting drug combinations based on total equivalent dose (dose intensity)
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamid | 1990 |
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).
Topics: Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cy | 1990 |
The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; C | 1990 |
Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervous Syste | 1990 |
[Chemotherapy testing for human ovarian cancer using in vitro colony assay].
Topics: Altretamine; Antineoplastic Agents; Bleomycin; Cell Division; Cells, Cultured; Cisplatin; Colony-For | 1985 |
Small cell carcinoma of the ovary: a rapidly lethal tumor occurring in the young.
Topics: Adolescent; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small | 1985 |
Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo | 1989 |
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc | 1989 |
Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1989 |
Management of recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 1989 |
Treatment of advanced ovarian cancer with sequential combination chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1987 |
Combined modality treatment for stage III ovarian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Combined Chemothe | 1985 |
Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo | 1986 |
Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1986 |
Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali | 1986 |
[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1986 |
Changes in erythropoiesis due to radiation or chemotherapy as studied by flow cytometric determination of peripheral blood reticulocytes.
Topics: Altretamine; Animals; Blood Cell Count; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Dru | 1986 |
Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Topics: Altretamine; Animals; Antineoplastic Agents; Female; Humans; Kinetics; Mice; Mice, Nude; Neoplasm Tr | 1986 |
Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
Topics: Adult; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dox | 1987 |
Acute myelocytic leukemia in a patient treated with hexamethylmelamine.
Topics: Aged; Altretamine; Female; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Ovarian Neo | 1986 |
Computed tomography prior to surgery for ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1986 |
Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1987 |
[Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1987 |
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car | 1987 |
The treatment of advanced stage ovarian carcinoma with a combination of chemotherapy, radiotherapy, and radiosensitizer: report of a pilot study from the National Cancer Institute.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Cyclophospham | 1987 |
Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo | 1987 |
Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1988 |
Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma.
Topics: Abdomen; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispla | 1988 |
An interaction between cytostatic and anticonvulsant drugs.
Topics: Adenocarcinoma, Papillary; Adult; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carba | 1988 |
The role of cytoreduction in ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1988 |
Advanced carcinoma of the ovary with central nervous system relapse.
Topics: Adenocarcinoma; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1988 |
The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1988 |
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Topics: Altretamine; Cyclophosphamide; Female; Humans; Ovarian Neoplasms; Triazines | 1988 |
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
Topics: Adenocarcinoma; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclop | 1985 |
Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modali | 1985 |
Single agent vs. combination chemotherapy for ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1985 |
Intraperitoneal chemotherapy for advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1985 |
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Topics: Adenocarcinoma; Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1985 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |
Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1985 |
Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Topics: Aclarubicin; Adolescent; Adult; Aged; Altretamine; Animals; Antibiotics, Antineoplastic; Antineoplas | 1985 |
The treatment of ovarian cancer by a multimodality approach: remission induction with chemotherapy--hexa PAMP and PAMP regimens--followed by whole-abdominal radiation.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1985 |